glp 1 agonists approved for weight loss Comparing Ozempic, Wegovy and Other GLP-1 Drugs GLP-1 medications are marketed to

Peptides with short half-lives were often dismissed because efficacy could not be sustained, even when acute biological effects were robust

However, hypoglycemia occurred more frequently with insulin glargine treatment, especially with background sulfonylurea therapy80)

These weight-loss medications are gaining popularity, but they can be misunderstood

A doctor can adjust the dose to balance results with side effects

Back Mojsov, S, Weir, GC, Habener, JF (Feb 1987) 'Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas', Journal of Clinical Investigation , 79, 616-19